Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers

OBJECTIVE--To define the region on human chromosome 19 carrying the gene for malignant hyperthermia susceptibility and to evaluate the use of flanking DNA markers in diagnosing susceptibility. DESIGN--Prospective molecular genetic linkage studies in a large malignant hyperthermia pedigree. SETTING--...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1991-11, Vol.303 (6812), p.1225-1228
Main Authors: Healy, S J, Heffron, J J, Lehane, M, Bradley, D G, Johnson, K, McCarthy, T V
Format: Article
Language:English
Subjects:
Chromosomes
Chromosomes, Human, Pair 19 - physiology
Contracture
Disease Susceptibility
DNA
Evaluation Studies as Topic
Female
Genes
Genetic Linkage - physiology
Genetic loci
Genetic mapping
Genetic Markers
Genetic Techniques
Humans
Lod Score
Male
Malignant hyperthermia
Malignant Hyperthermia - genetics
Muscle Contraction - physiology
Pedigree
Phenotypes
Polymorphism, Restriction Fragment Length
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE--To define the region on human chromosome 19 carrying the gene for malignant hyperthermia susceptibility and to evaluate the use of flanking DNA markers in diagnosing susceptibility. DESIGN--Prospective molecular genetic linkage studies in a large malignant hyperthermia pedigree. SETTING--Irish malignant hyperthermia testing centre. SUBJECTS--A large Irish malignant hyperthermia pedigree. MAIN OUTCOME MEASURES--Routine diagnosis of susceptibility to malignant hyperthermia with in vitro contracture test on muscle biopsy specimens and genetic linkage between susceptibility and polymorphic DNA markers in a malignant hyperthermia family. RESULTS--Genetic typing of polymorphic DNA markers in a large Irish malignant hyperthermia pedigree generated a lod score of greater than 3 for the marker D19S9 and showed that the gene for susceptibility is flanked by the markers D19S9 and D19S16. These tightly linked flanking markers allowed non-invasive presymptomatic diagnosis of susceptibility in five untested subjects in the large pedigree with an accuracy of greater than 99.7%. CONCLUSIONS--DNA markers flanking the gene for susceptibility to malignant hyperthermia can be used with high accuracy to diagnose susceptibility in subjects in large known malignant hyperthermia pedigrees and may replace the previous in vitro contracture test for diagnosing this inherited disorder in large families with malignant hyperthermia.
ISSN:0959-8138
1468-5833
1756-1833
DOI:10.1136/bmj.303.6812.1225